Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-MGD Participants | Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study. |
| |
| Mild-Moderate MGD Participants | Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study. |
| |
| Severe MGD Participants | Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Meibum Expression | Procedure | Meibum expression as per protocol. No investigational drug is administered in this study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Meibum Quality Score in the Study Eye as Assessed by the Investigator Using a 4-Point Scale | Day 22 |
Not provided
Not provided
Inclusion Criteria:
-Participants characterized as with or without Meibomian Gland Dysfunction.
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants characterized as with or without Meibomian Gland Dysfunction.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Houston | Texas | United States | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37910805 | Derived | Ajouz L, Hallak J, Naik R, Nguyen A, Zhao C, Robinson MR, Nichols KK. Evaluation of the Impact of Meibomian Gland Dysfunction Using a Novel Patient-Reported Outcome Instrument. J Ocul Pharmacol Ther. 2024 Jan-Feb;40(1):48-56. doi: 10.1089/jop.2023.0080. Epub 2023 Nov 1. | |
| 37643299 | Derived | Ajouz L, Nguyen A, Zhao C, Robinson MR, Nichols KK. Exploring Signs and Symptoms Associated with Meibomian Gland Dysfunction for Use as Clinical Trial Endpoints. J Ocul Pharmacol Ther. 2023 Nov;39(9):611-621. doi: 10.1089/jop.2023.0064. Epub 2023 Aug 29. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Tears
| London |
| United Kingdom |
| 37466951 | Derived | Nagar S, Ajouz L, Nichols KK, Kumar S, Zhao C, Naidoo KK, Robinson MR, Borchman D. Relationship Between Human Meibum Lipid Composition and the Severity of Meibomian Gland Dysfunction: A Spectroscopic Analysis. Invest Ophthalmol Vis Sci. 2023 Jul 3;64(10):22. doi: 10.1167/iovs.64.10.22. |